Syntr Health Technologies and HAPPYBOND team up to combat canine osteoarthritis

Syntr Health Technologies, Inc. and HAPPYBOND, Inc have collaborated to maximize SYNTR's patented SynterFugeK9 System and HAPPYBOND's uniquely formulated and patented collagen supplement, to develop an advanced, highly synergistic therapy for treating knee and joint osteoarthritis.

"We are excited to combine SYNTR's autologous microsized fat tissue to replenish lost fat in the joints with HAPPYBOND's unique pet supplements for cartilage regeneration. This will give our beloved canine friends the opportunity for a new lease on life,'' expressed Ahmed Zobi, CEO of Syntr Health, in a company release.¹

"Veterinarians and dog owners will have an enhanced therapy to combat one of the most common joint diseases experienced by dogs in the US,” he added.

"One of the key issues experienced by dogs as they age is lack of mobility. We are super excited to join forces with an amazing solution to give our best friends the joy of movement back," said Anja Skodda, CEO and Chief Scientist of HAPPYBOND. "This partnership will open up more research on current and future solutions to combat degenerative joint disease in canines."

This partnership aims to achieve the best results by using the canine's own fat tissue processed with the SyntrFugeK9 system, along with with pre- and post- oral supplementation with HAPPYBOND's Collagen+, which has been proven to induce and improve biosynthesis of collagen and the extracellular matrix in cartilage. Together, the companies will create a natural, simple, and affordable treatment method for canine osteoarthritis.

Reference

Syntr Health Technologies announces partnership with HAPPYBOND to combat canine osteoarthritis. Syntr Health Technologies, Inc. News release. Syntr Health Technologies, Inc. September 15, 2022. Accessed September 19, 2022. https://www.prnewswire.com/news-releases/syntr-health-technologies-announces-partnership-with-happybond-to-combat-canine-osteoarthritis-301622854.html